27
Apr
2008
Posted in I - Series B, Q - 1Q08, R - ROCKY MOUNTAIN, X - CNS, X - Stem Cell
Q Therapeutics (Salt Lake City, UT) a development-stage company focused on stem cell therapies for CNS-related disease closed the first tranche of a $15M Series B financing. Participants include vSpring Capital, Invitrogen, Epic Ventures, Toucan Capital, University of Utah Research Foundation, Salt Lake Life Science Angels and Q management.